Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 45,506

Document Document Title
WO/2014/048865
The invention provides novel compounds having the general formula (I) wherein R1, Y, A, W, R2, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2014/050779
To provide a combination therapy for cancer, which comprises a combination of a GSK3 inhibitor and an anti-DR5 antibody. Provided are a pharmaceutical product and a combination therapy, each of which comprises a combination of various an...  
WO/2014/052896
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprisi...  
WO/2014/050003
[Problem] To provide a substance capable of safely and effectively modulating expression of a period gene. [Solution] An expression modulator for a period gene containing Pelargonium plant extract as an effective component.  
WO/2014/052789
The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.  
WO/2014/052849
The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment o...  
WO/2014/052859
The present invention relates to intranasally administered pharmaceutical compositions for the treatment of headaches, such as migraines. Such pharmaceutical compositions comprise benzyl alcohol or a combination of benzyl alcohol and tet...  
WO/2014/052837
A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more po...  
WO/2014/050084
The purpose of the invention is to create a compound that selectively activates liver glucokinase and in particular to provide a drug having low hypoglycemic risk for the treatment and prevention of diabetes and impaired glucose toleranc...  
WO/2014/052766
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dem...  
WO/2014/048380
A preparation method of an agomelatine solid preparation comprises: mixing agomelatine or pharmaceutically acceptable salts with cross-linked polyvinylpolypyrrolidone; hot-melting the mixture to prepare particles; and then mixing the par...  
WO/2014/052394
Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and ...  
WO/2014/048945
The present invention relates to BET protein-inhibiting 5-aryl triazole azepines, particularly BRD4-inhibiting 5-aryl triazole azepines of general formula (I) in which R1, R2, R3 and R4 have the meanings indicated in general formula (I)....  
WO/2014/048033
The present invention relates to polymorphic forms of the compound of Formula (I) (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(1l)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as ca...  
WO/2014/052933
This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridop...  
WO/2014/049471
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2014/049366
Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of s...  
WO/2014/047707
The present invention relates to a compound of formula (I) or to a pharmaceutically acceptable salt thereof with analgesic activity. In particular, the compounds according to the present invention are useful for treating or preventing ac...  
WO/2014/049133
The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive a...  
WO/2014/052427
The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alph...  
WO/2014/052807
Methods for alleviating symptoms related to Multiple Sclerosis by administration of apoaequorin are provided by the present invention. Such symptoms include, for example, sleep quality, energy quality, mood quality, memory quality or pain.  
WO/2014/052398
The present invention relates to spirocyclic indane imidazole 4-amines and their use as inhibitors of the β-secretase enzyme (BACEl) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic...  
WO/2014/052669
Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.  
WO/2014/051388
The present invention relates to a pharmaceutical composition comprising a sulfamide derivative having an adamantyl group as an active ingredient for preventing or treating brain diseases or ischemic heart diseases. The sulfamide derivat...  
WO/2014/048370
Methods and compounds for treating, inhibiting, and preventing traumatic brain injury are provided. Methods include administering 7,8-dihydroxyflavone and derivatives thereof.  
WO/2014/051567
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first...  
WO/2014/048165
Disclosed is a compound as a potassium channel modulator, which is a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Such compound can be used to prepare drugs for increasing the flow of ions in potassium c...  
WO/2014/052461
The invention features compositions for use in increasing neuron or neurite growth, including for the treatment of Central Nervous System (CNS) injury, such as human arylsulfatase B.  
WO/2014/052659
The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention ...  
WO/2014/048071
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/046391
The present invention relates to a pharmaceutical composition for treating or preventing protein tyrosine phosphatase sigma (PTPσ)-mediated diseases, and provides a pharmaceutical composition for treating or preventing PTPσ-mediate dis...  
WO/2014/046544
The present invention relates to compounds compound according to Formula (1): and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have serotonin (5-HT) transporter inhibitory effects and 5-HT 2C receptor...  
WO/2014/046247
 Provided is a method for adjusting the balance of TNF-R1 and TNF-R2 in cells present at a target organ, tissue or site. In the adjustment method provided by the present invention, (1) if raising the abundance of TNF-R2 present in a ta...  
WO/2014/045156
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...  
WO/2014/045031
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing...  
WO/2014/044790
The present invention relates to a DYRK1A inhibitor or an inhibitor of DYRK1A gene expression for use in the treatment or prevention of hypothyroidism in a Down Syndrome patient.  
WO/2014/047116
Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, ...  
WO/2014/045162
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of trea...  
WO/2014/047323
Embodiments of the invention generally relate to methods and supplements for treating post-traumatic stress disorder in human beings. Other embodiments of the invention generally relate to methods and supplements for improving sleep effi...  
WO/2014/044721
The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with cha...  
WO/2014/047153
The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition...  
WO/2014/046472
The present invention provides a rivastigmine medicine having improved stability. The invention also provides a method, for packing pharmaceutical medicines containing rivastigmine, capable of improving stability.  
WO/2014/041007
The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy...  
WO/2014/040969
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N1) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N2) is phenyl or pyridinyl...  
WO/2014/041106
The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N= or ...  
WO/2014/041111
Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.  
WO/2014/041179
A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist.  
WO/2014/040228
The present invention relates to the stabilised amorphous form of the compound of formula (I), to a process for its preparation and also to pharmaceutical compositions or medicaments containing it.  
WO/2014/043685
Disclosed are compositions, such as liquid and solid nutritional compositions, that contain beta-hydroxy-beta-methylbutyric acid and optionally at least one protein, carbohydrate, fat, or a combination of protein, carbohydrate, and fat. ...  
WO/2014/043330
Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods ...  

Matches 51 - 100 out of 45,506